Cervista HPV assays for fine‐needle aspiration specimens are a valid option for human papillomavirus testing in patients with oropharyngeal carcinoma
Open Access
- 11 December 2013
- journal article
- research article
- Published by Wiley in Cancer Cytopathology
- Vol. 122 (2) , 96-103
Abstract
BACKGROUND: The objectives of this study were to evaluate the validity of Cervista human papillomavirus (HPV) assays in head and neck fine‐needle aspiration (FNA) specimens from patients with head and neck squamous carcinomas and to verify that the Cervista assay in FNA specimens is a valid option for determining HPV status in patients with oropharyngeal carcinomas.METHODS: The authors retrospectively retrieved 64 head and neck FNA specimens from patients who had head and neck squamous carcinoma. The specimens were tested for HPV types 16 and 18 (HPV16/18) and for high‐risk (HR) HPV DNA using the Cervista HPV16/18 and HPV HR assays, respectively. The results from those assays were compared with the results from polymerase chain reaction (PCR)‐based HPV assays in the same tissues and with the results from HPV in situ hybridization assays/p16 immunostaining in the corresponding primary tumors.RESULTS: In total, 64 FNA specimens were analyzed. The Cervista HPV16/18 and/or HPV HR assays were positive in 48 of 64 specimens (75%), and there was a predominance of HPV16 (42 of 48 specimens; 88%). In the 49 specimens that had PCR‐based test results, overall agreement with Cervista assay results was 96% (47 of 49 specimens; κ = 0.883). In the 49 specimens that had PCR‐based HPV16/18 genotyping results, overall agreement with the Cervista HPV16/18 results was 94% (46 of 49 specimens; κ = 0.847). In the 36 primary carcinoma specimens that had valid HPV in situ hybridization/p16 immunostaining results, overall agreement with the Cervista assay results was 92% (33 of 36 specimens; κ = 0.679).CONCLUSIONS: Cervista HPV16/18 and Cervista HPV HR testing of head and neck FNA specimens is a valid option for determining HPV16/18 status in patients with oropharyngeal carcinoma. Cancer (Cancer Cytopathol) 2014;122:96–103. © 2013 American Cancer Society.Keywords
This publication has 22 references indexed in Scilit:
- HPV Specific Testing: A Requirement for Oropharyngeal Squamous Cell Carcinoma PatientsHead and Neck Pathology, 2012
- Epidemiology and Clinical Aspects of HPV in Head and Neck CancersHead and Neck Pathology, 2012
- Human Papillomavirus as a Marker of the Natural History and Response to Therapy of Head and Neck Squamous Cell CarcinomaSeminars in Radiation Oncology, 2012
- Evaluation of Human Papilloma Virus Diagnostic Testing in Oropharyngeal Squamous Cell Carcinoma: Sensitivity, Specificity, and Prognostic DiscriminationClinical Cancer Research, 2011
- HPV-associated head and neck cancer: a virus-related cancer epidemicThe Lancet Oncology, 2010
- Human Papillomavirus and Survival of Patients with Oropharyngeal CancerNew England Journal of Medicine, 2010
- Burden of potentially human papillomavirus-associated cancers of the oropharynx and oral cavity in the US, 1998-2003Cancer, 2008
- Incidence Trends for Human Papillomavirus–Related and –Unrelated Oral Squamous Cell Carcinomas in the United StatesJournal of Clinical Oncology, 2008
- Trends in head and neck cancer incidence in relation to smoking prevalenceCancer, 2007
- Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancerInternational Journal of Cancer, 2006